Enimmune (6564.TWO) Stock Price

Enimmune Price

CLOSED
16.25
​
Market closed

Revenue has compounded at 54.5% per year over the past 10 years to 48.19 M TWD. Enimmune's net margin stands at -341.0%, down from -43.0% several years earlier.

Enimmune stock price

Access this data via the Eulerpool API

Enimmune business model & stock analysis

Enimmune Corp. engages in the research, development of new drugs. The company is headquartered in Taipei City, Taipei. The company went IPO on 2018-09-18. The firm's new drug products include biological agents, monoclonal antibodies, vaccines, and small molecule drugs. The firm mainly conducts drug testing business, biotechnology service business, international trade business, western medicine wholesale and retail business. The product is Tuberculin PPD.

Frequently asked questions about Enimmune

Converted at the current exchange rate, the Enimmune share trades at 0.45 EUR (16.25 TWD).

The revenue cannot currently be calculated for Enimmune.

The profit cannot currently be calculated for Enimmune.

The P/E ratio cannot be calculated for Enimmune at the moment.

The P/S cannot be calculated for Enimmune currently.

The Eulerpool Quality Score for Enimmune is 3/10.

The ISIN of Enimmune is TW0006564008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Enimmune is 6564.TWO. The ticker symbol is used to trade Enimmune shares on the stock exchange.

Fair ValueTerminal
14.95 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Taiwan
Currency
TWD
Initial public offering
Sep 18, 2018
ISIN
TW0006564008
Cusip
Y2294W103
Market capitalization
1.17 B TWDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
7.83
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-92.38 %
Last updated Oct 15, 2026, 4:54 AM

Enimmune Peer Group

Enimmune FIGI

6564:TT (Taipei Stock Exchange) · BBG00M0C0FW5

All fundamentals and in-depth analysis of Enimmune

Our stock analysis for Enimmune stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Enimmune. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.